Aberrant DNA methylation of the transcription factor C/EBPα in acute myelogenous leukemia

Leukemia Research

Volumn 33, Issue 3, 2009, Pages 443-449

  Jost, Edgar ^a   Ó, Nicole do ^a   Wilop, Stefan ^a   Herman, James G ^b   Osieka, Rainhardt ^a   Galm, Oliver ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute myelogenous leukemia; C EBP; Cell cycle; DNA methylation; Epigenetics; Transcriptional silencing

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CCAAT ENHANCER BINDING PROTEIN ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SILENCER ELEMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELLS, CULTURED; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 58549105082     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.07.027     Document Type: Article

References (34)

1. Tenen D.G. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3 (2003) 89-101
2. Frohling S., and Dohner H. Disruption of C/EBPalpha function in acute myeloid leukemia. N Engl J Med 351 (2004) 2370-2372
3. Mueller B.U., and Pabst T. C/EBPalpha and the pathophysiology of acute myeloid leukemia. Curr Opin Hematol 13 (2006) 7-14
4. Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27 (2001) 263-270
5. Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer 4 (2004) 394-400
6. Jones P.A., and Baylin S.B. The epigenomics of cancer. Cell 128 (2007) 683-692
7. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349 (2003) 2042-2054
8. Esteller M. Epigenetics in cancer. N Engl J Med 358 (2008) 1148-1159
9. Galm O., Herman J.G., and Baylin S.B. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 20 (2006) 1-13
10. Gore S.D., Baylin S., Sugar E., Carraway H., Miller C.B., Carducci M., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66 (2006) 6361-6369
11. Issa J.P. DNA methylation as a therapeutic target in cancer. Clin Cancer Res 13 (2007) 1634-1637
12. Timchenko N., Wilson D.R., Taylor L.R., Abdelsayed S., Wilde M., Sawadogo M., et al. Autoregulation of the human C/EBP alpha gene by stimulation of upstream stimulatory factor binding. Mol Cell Biol 15 (1995) 1192-1202
13. Tada Y., Brena R.M., Hackanson B., Morrison C., Otterson G.A., and Plass C. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 98 (2006) 396-406
14. Bennett K.L., Hackanson B., Smith L.T., Morrison C.D., Lang J.C., Schuller D.E., et al. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res 67 (2007) 4657-4664
15. Galm O., Wilop S., Luders C., Jost E., Gehbauer G., Herman J.G., et al. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol 84 Suppl 1 (2005) 39-46
16. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (1996) 9821-9826
17. Galm O., and Herman J.G. Methylation-specific polymerase chain reaction. Meth Mol Med 113 (2005) 279-291
18. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
19. Johnson P.F. Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. J Cell Sci 118 (2005) 2545-2555
20. Cameron E.E., Baylin S.B., and Herman J.G. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 94 (1999) 2445-2451
21. Sherr C.J., and Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9 (1995) 1149-1163
22. Kirstetter P., Schuster M.B., Bereshchenko O., Moore S., Dvinge H., Kurz E., et al. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell 13 (2008) 299-310
23. Keeshan K., He Y., Wouters B.J., Shestova O., Xu L., Sai H., et al. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell 10 (2006) 401-411
24. Helbling D., Mueller B.U., Timchenko N.A., Schardt J., Eyer M., Betts D.R., et al. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood 106 (2005) 1369-1375
25. Valk P.J., Verhaak R.G., Beijen M.A., Erpelinck C.A., Barjesteh van Waalwijk van Doorn-Khosrovani S., Boer J.M., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350 (2004) 1617-1628
26. Wouters B.J., Jorda M.A., Keeshan K., Louwers I., Erpelinck-Verschueren C.A., Tielemans D., et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 110 (2007) 3706-3714
27. Agrawal S., Hofmann W.K., Tidow N., Ehrich M., van den Boom D., Koschmieder S., et al. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 109 (2007) 3895-3905
28. Chim C.S., Wong A.S., and Kwong Y.L. Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia. Br J Haematol 119 (2002) 988-990
29. Hackanson B., Bennett K.L., Brena R.M., Jiang J., Claus R., Chen S.S., et al. Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res 68 (2008) 3142-3151
30. Schepers H., Wierenga A.T., van Gosliga D., Eggen B.J., Vellenga E., and Schuringa JJ. Reintroduction of C/EBP{alpha} in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood 110 (2007) 1317-1325
31. Hsu C.L., King-Fleischman A.G., Lai A.Y., Matsumoto Y., Weissman I.L., and Kondo M. Antagonistic effect of CCAAT enhancer-binding protein-alpha and Pax5 in myeloid or lymphoid lineage choice in common lymphoid progenitors. Proc Natl Acad Sci USA 103 (2006) 672-677
32. Pongubala J.M., Northrup D.L., Lancki D.W., Medina K.L., Treiber T., Bertolino E., et al. Transcription factor EBF restricts alternative lineage options and promotes B cell fate commitment independently of Pax5. Nat Immunol 9 (2008) 203-215
33. van Engeland M., Roemen G.M., Brink M., Pachen M.M., Weijenberg M.P., de Bruine A.P., et al. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 21 (2002) 3792-3795
34. Jost E., do Ó N., Dahl E., Maintz C.E., Jousten P., Habets L., et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia 21 (2007) 505-510